Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Recommendations	Merck KGaA price target lowered to EUR 200 from EUR 208 at Credit Suisse » 15:36 05/13/22 05/13 15:36 05/13/22 15:36 MKKGY Merck KGaA $33.31 / -1.765 (-5.03%) Credit Suisse analyst… Credit Suisse analyst Trung Huynh lowered the firm's price target on Merck KGaA to EUR 200 from EUR 208 and keeps an Outperform rating on the shares. ShowHide Related Items >><< Company News Street Research MKKGY Merck KGaA $33.31 / -1.765 (-5.03%) 01/05/22 F-star Therapeutics announces Merck KGaA exercises fourth licensing option MKKGY Merck KGaA $33.31 / -1.765 (-5.03%) 04/29/22 Morgan Stanley Merck KGaA price target raised to EUR 225 from EUR 220 at Morgan Stanley 04/04/22 Morgan Stanley Merck KGaA price target lowered to EUR 220 from EUR 230 at Morgan Stanley 01/04/22 JPMorgan Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan 09/17/21 Morgan Stanley Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
Recommendations	Merck KGaA price target raised to EUR 225 from EUR 220 at Morgan Stanley » 14:23 04/29/22 04/29 14:23 04/29/22 14:23 MKKGY Merck KGaA $36.56 / +0.71 (+1.98%) Morgan Stanley analyst… Morgan Stanley analyst Mark Purcell raised the firm's price target on Merck KGaA to EUR 225 from EUR 220 and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< Company News Street Research MKKGY Merck KGaA $36.56 / +0.71 (+1.98%) 01/05/22 F-star Therapeutics announces Merck KGaA exercises fourth licensing option MKKGY Merck KGaA $36.56 / +0.71 (+1.98%) 04/04/22 Morgan Stanley Merck KGaA price target lowered to EUR 220 from EUR 230 at Morgan Stanley 01/04/22 JPMorgan Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan 09/17/21 Morgan Stanley Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley 09/13/21 Deutsche Bank Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank

Over a month ago
Recommendations	Merck KGaA price target lowered to EUR 220 from EUR 230 at Morgan Stanley » 14:16 04/04/22 04/04 14:16 04/04/22 14:16 MKKGY Merck KGaA $42.22 / +0.41 (+0.98%) Morgan Stanley analyst… Morgan Stanley analyst Mark Purcell lowered the firm's price target on Merck KGaA to EUR 220 from EUR 230 and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< Company News Street Research MKKGY Merck KGaA $42.22 / +0.41 (+0.98%) 01/05/22 F-star Therapeutics announces Merck KGaA exercises fourth licensing option MKKGY Merck KGaA $42.22 / +0.41 (+0.98%) 01/04/22 JPMorgan Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan 09/17/21 Morgan Stanley Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley 09/13/21 Deutsche Bank Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank 09/10/21 JPMorgan Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan

Over a quarter ago
Hot Stocks	F-star Therapeutics announces Merck KGaA exercises fourth licensing option » 08:07 01/05/22 01/05 08:07 01/05/22 08:07 FSTX F-star Therapeutics $4.96 / -0.44 (-8.15%) , MKKGY Merck KGaA $49.71 / -0.74 (-1.47%) F-star Therapeutics… F-star Therapeutics (FSTX) announced that Ares Trading, an affiliate of Merck KGaA (MKKGY), Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will be responsible for all future development and commercialization costs and will pay future success-based milestones and royalties on any net sales, resulting from programs covered by the agreement. Eliot Forster, CEO of F-star Therapeutics, Inc, said: "We were delighted to see the recent data presented by Merck KGaA, Darmstadt, Germany, from our long-standing collaboration at the recent SITC conference, demonstrating the unique potential of the F-star bispecific platform. This latest licensing option marks another positive milestone in our collaboration and it is exciting to see our partner successfully progress another mAb2 based program. Along with our internal pipeline, we believe all of these next generation immuno-oncology programs will make a real difference to the lives of patients with cancer." ShowHide Related Items >><< Company News Street Research Earnings Syndicate FSTX FSTX F-star Therapeutics $4.96 / -0.44 (-8.15%) 12/07/21 F-star Therapeutics to present FS222 trial-in-progress update at ESMO-IO 2021 11/29/21 F-star Therapeutics to host virtual R&D day on December 6 10/20/21 F-star Therapeutics announces license agreement with Janssen 09/16/21 F-star Therapeutics to present FS120 Phase 1 trial-in-progress update FSTX MKKGY FSTX F-star Therapeutics $4.96 / -0.44 (-8.15%) 11/18/21 Ladenburg F-star Therapeutics price target lowered to $15 from $27 at Ladenburg 11/12/21 Oppenheimer F-star Therapeutics price target raised to $33 from $30 at Oppenheimer 07/08/21 SVB Leerink F-star Therapeutics initiated with an Outperform at SVB Leerink 06/09/21 B. Riley B. Riley starts F-star Therapeutics at Buy, sees 307% potential upside MKKGY Merck KGaA $49.71 / -0.74 (-1.47%) 01/04/22 JPMorgan Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan 09/17/21 Morgan Stanley Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley 09/13/21 Deutsche Bank Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank 09/10/21 JPMorgan Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan FSTX FSTX F-star Therapeutics $4.96 / -0.44 (-8.15%) 11/10/21 F-star Therapeutics reports Q3 EPS (52c), consensus (58c) 08/12/21 F-star Therapeutics reports Q2 EPS (92c), consensus (74c) 09 May
Recommendations	Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan » 14:39 01/04/22 01/04 14:39 01/04/22 14:39 MKKGY Merck KGaA $50.45 / -1.65 (-3.17%) JPMorgan analyst Richard… JPMorgan analyst Richard Vosser raised the firm's price target on Merck KGaA to EUR 270 from EUR 245 and keeps an Overweight rating on the shares. ShowHide Related Items >><< Street Research MKKGY Merck KGaA $50.45 / -1.65 (-3.17%) 09/17/21 Morgan Stanley Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley 09/13/21 Deutsche Bank Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank 09/10/21 JPMorgan Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan 09/02/21 Barclays Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays

Conference/Events	Stifel healthcare analysts to hold an analyst/industry conference call » 14:25 10/14/21 10/14 14:25 10/14/21 14:25 TPTX Turning Point Therapeutics $49.07 / +2.065 (+4.39%) , RHHBY Roche $48.22 / -0.01 (-0.02%) , NVS Novartis $82.57 / +0.105 (+0.13%) , MKKGY Merck KGaA $44.51 / +1.15 (+2.65%) , MRTX Mirati Therapeutics $176.55 / +4.72 (+2.75%) , AMGN Amgen $207.22 / +3.73 (+1.83%) , RVMD Revolution Medicines $28.65 / +0.79 (+2.84%) Healthcare Analysts,… Healthcare Analysts, along with Dr. David Ross Camidge and Dr. Vamsidhar Velcheti, discuss how TPTX's repotrectinib safety data might inform 1L or 2L market share in ROS1+ NSCLC, the opportunity for TPTX's TPX-022 MET inhibitor in METex14 NSCLC and Amgen's Lumakras KRAS G12C NSCLC launch on an Analyst/Industry conference call to be held on October 14 at 3 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TPTX RVMD RHHBY NVS MRTX MKKGY AMGN TPTX Turning Point Therapeutics $49.07 / +2.065 (+4.39%) 10/13/21 Turning Point, EQRx team to evaluate elzovantinib/aumolertinib combo in NSCLC 10/08/21 Turning Point Therapeutics presents TRIDENT-1 clinical data for repotrectinib 10/07/21 Turning Point Therapeutics provides regulatory update 10/07/21 Turning Point presents updated preliminary clinical data for elzovantinib RVMD Revolution Medicines $28.65 / +0.79 (+2.84%) 06/24/21 Revolution Medicines publishes data on mTORC1-selective inhibitors 06/10/21 Revolution Medicines to host webcast on studies of RAS inhibitors 05/03/21 Revolution Medicines highlights board of directors nominees for upcoming meeting 04/30/21 Revolution Medicines does not expect RMC-4630, sotorasib data in 2021 RHHBY Roche $48.22 / -0.01 (-0.02%) 10/14/21 Genentech announces new Espryng efficacy, safety data at ECTRIMS 10/13/21 Roche says new long-term data reinforce benefit of ocrelizumab in relapsing MS 10/11/21 Sarepta announces functional data from SRP-9001 development program 10/08/21 Roche's gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's NVS Novartis $82.57 / +0.105 (+0.13%) 10/11/21 Novartis' Sandoz completes acquisition of GSK's cephalosporin business 10/06/21 Rafael names Mary Margaret Huizinga as chief development and medical officer 10/01/21 Sandoz resolves legacy U.S. federal government civil investigation 10/01/21 Three generic drug makers to pay $447.2M to settle price-fixing claims, DOJ says MRTX Mirati Therapeutics $176.55 / +4.72 (+2.75%) 10/07/21 Mirati, Sanofi to collaborate on adagrasib-SHP2 Inhibitor combo 09/20/21 Mirati Therapeutics announces results from Phase 2 study of MRTX-500 09/20/21 Mirati Therapeutics appoints David Meek as Chief Executive Officer 09/20/21 Mirati Therapeutics announce Phase 2 topline results for adagrasib MKKGY Merck KGaA $44.51 / +1.15 (+2.65%) 06/14/21 G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela AMGN Amgen $207.22 / +3.73 (+1.83%) 10/08/21 AstraZeneca announces Tezepelumab granted orphan drug designation 10/07/21 Amgen reports Phase 1b data from Lumakras combination in cancer 10/07/21 Amgen, Neumora enter collaboration to advance neuroscience discovery 10/04/21 BioMarin hires Bernstein as CMO, Vedantham as senior VP TPTX RHHBY NVS MKKGY MRTX AMGN RVMD TPTX Turning Point Therapeutics $49.07 / +2.065 (+4.39%) 10/12/21 H.C. Wainwright Turning Point price target lowered to $162 from $178 at H.C. Wainwright 10/11/21 JMP Securities Turning Point downgraded to Market Perform from Outperform at JMP Securities 10/08/21 Roth Capital Turning Point selloff brings 'bargain value,' says Roth Capital 10/08/21 Wedbush Turning Point Therapeutics price target lowered to $125 from $166 at Wedbush RHHBY Roche $48.22 / -0.01 (-0.02%) 10/13/21 Morgan Stanley Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley 09/20/21 Citi Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote 09/09/21 RBC Capital Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital 09/07/21 UBS Roche price target raised to CHF 350 from CHF 345 at UBS NVS Novartis $82.57 / +0.105 (+0.13%) 10/12/21 Berenberg Novartis price target lowered to CHF 88 from CHF 96 at Berenberg 10/08/21 UBS Novartis price target lowered to CHF 92 from CHF 95 at UBS 09/29/21 Stifel Blueprint Medicines rersumed with a Hold at Stifel 09/20/21 Deutsche Bank Novartis downgraded to Sell from Hold at Deutsche Bank MKKGY Merck KGaA $44.51 / +1.15 (+2.65%) 09/17/21 Morgan Stanley Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley 09/13/21 Deutsche Bank Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank 09/10/21 JPMorgan Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan 09/02/21 Barclays Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays MRTX Mirati Therapeutics $176.55 / +4.72 (+2.75%) 09/22/21 Stifel Mirati Therapeutics initiated with a Buy at Stifel 09/22/21 Citi Mirati Therapeutics price target raised to $244 from $232 at Citi 09/21/21 Oppenheimer Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer 09/07/21 JPMorgan Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan AMGN Amgen $207.22 / +3.73 (+1.83%) 10/04/21 Piper Sandler Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler 09/23/21 Daiwa Amgen downgraded to Neutral from Outperform at Daiwa RVMD Revolution Medicines $28.65 / +0.79 (+2.84%) 09/22/21 Stifel Revolution Medicines initiated with a Hold at Stifel 08/17/21 H.C. Wainwright Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright 08/12/21 Fly Intel: Top five analyst downgrades 08/12/21 Guggenheim Revolution Medicines price target lowered to $34 from $52 at Guggenheim TPTX RVMD RHHBY NVS MRTX AMGN TPTX Turning Point Therapeutics $49.07 / +2.065 (+4.39%) 08/09/21 Turning Point Therapeutics reports Q2 EPS (1.14c), consensus ($1.21) RVMD Revolution Medicines $28.65 / +0.79 (+2.84%) 08/11/21 Revolution Medicines reports Q2 EPS (60c), consensus (48c) 05/10/21 Revolution Medicines reports Q1 EPS (53c), consensus (52c) RHHBY Roche $48.22 / -0.01 (-0.02%) 07/22/21 Roche reports 1H21 core EPS CHF10.56 vs. CHF10.44 last year 04/21/21 Roche reports Q1 group sales CHF 14.93B vs. CHF 15.14B last year NVS Novartis $82.57 / +0.105 (+0.13%) 07/21/21 Novartis continues to expect FY21 core operating income to grow mid single digit 07/21/21 Novartis reports Q2 core EPS $1.66, consensus $1.52 04/27/21 Novartis sees FY21 core operating income to grow mid single digit percentage 04/27/21 Novartis reports Q1 core EPS $1.52, consensus $1.59 MRTX Mirati Therapeutics $176.55 / +4.72 (+2.75%) 08/05/21 Mirati Therapeutics reports Q2 EPS ($3.23), consensus ($2.40) 05/06/21 Mirati Therapeutics reports Q1 EPS ($2.67), consensus ($2.13) AMGN Amgen $207.22 / +3.73 (+1.83%) 08/03/21 Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.34 08/03/21 Amgen reports Q2 adjusted EPS $4.38, consensus $4.06 08/03/21 Notable companies reporting after market close 04/27/21 Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.80 04 Feb 28 Oct 27 Oct RHHBY NVS RHHBY Roche $48.22 / -0.01 (-0.02%) 10/14/21 White House close to nominating Robert Califf to head FDA, Washington Post says 09/09/21 Biden administration plans to lower prescription drug prices, WSJ reports 08/04/21 SoftBank builds $5B stake in Roche, Bloomberg reports 07/01/21 Roche won't confirm report of filing for approval of Alzheimer's drug, STAT says NVS Novartis $82.57 / +0.105 (+0.13%) 10/13/21 Drugmakers find new cancer risk in blood pressure drugs, Bloomberg says 07/21/21 Novartis CEO tells CNBC he still sees lower rates of non-COVID diagnoses RHHBY NVS MRTX AMGN RHHBY Roche $48.22 / -0.01 (-0.02%) 09/27/21 Acceleron up amid report of talks, Cowen says $180 per share 'too low' a price 09/07/21 Wall Street in Fives - Must Read Lists for Tuesday 09/07/21 Wall Street in Fives - Must Read Lists at Midday 09/07/21 Fly Intel: Pre-market Movers NVS Novartis $82.57 / +0.105 (+0.13%) 09/20/21 Wall Street in Fives - Must Read Lists for Monday 09/20/21 Wall Street in Fives - Must Read Lists at Midday 07/21/21 Wall Street in Fives - Must Read Lists at Midday 05/18/21 Before the Move: Watch Allogene ahead of ALLO-501 update MRTX Mirati Therapeutics $176.55 / +4.72 (+2.75%) 06/24/21 Fly Intel: After-Hours Movers AMGN Amgen $207.22 / +3.73 (+1.83%) 05/28/21 Wall Street in Fives - Must Read Lists for Friday 04/27/21 Fly Intel: After-Hours Movers 10/14/21 Healthcare 10/26/21 63rd Annual ASTRO Meeting 2021 11/08/21 PPharma Marketing USA 11/09/21 30th Annual Virtual Healthcare Conference 11/16/21 2021 Virtual Healthcare Conference 11/02/21 Amgen - AMGN 12/01/21 PDUFA Date for Tecentriq 12/19/21 PDUFA Date for Otezla NVS AMGN NVS Novartis $82.57 / +0.105 (+0.13%) 10/04/21 Novartis put volume heavy and directionally bearish AMGN Amgen $207.22 / +3.73 (+1.83%) 07/21/21 Unusually active option classes on open July 21st 07/08/21 Early notable gainers among liquid option names on July 8th 06/28/21 Amgen put volume heavy and directionally bearish 06/10/21 Unusually active option classes on open June 10th
Conference/Events	Stifel healthcare analysts to hold an analyst/industry conference call » 04:55 10/14/21 10/14 04:55 10/14/21 04:55 TPTX Turning Point Therapeutics $47.00 / +0.9 (+1.95%) , RHHBY Roche $48.22 / -0.01 (-0.02%) , NVS Novartis $82.47 / +0.425 (+0.52%) , MKKGY Merck KGaA $44.51 / +1.15 (+2.65%) , MRTX Mirati Therapeutics $171.89 / -6.27 (-3.52%) , AMGN Amgen $203.70 / +1.63 (+0.81%) , RVMD Revolution Medicines $27.77 / +0.385 (+1.41%) Healthcare Analysts,… Healthcare Analysts, along with Dr. David Ross Camidge and Dr. Vamsidhar Velcheti, discuss how TPTX's repotrectinib safety data might inform 1L or 2L market share in ROS1+ NSCLC, the opportunity for TPTX's TPX-022 MET inhibitor in METex14 NSCLC and Amgen's Lumakras KRAS G12C NSCLC launch on an Analyst/Industry conference call to be held on October 14 at 3 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TPTX RVMD RHHBY NVS MRTX MKKGY AMGN TPTX Turning Point Therapeutics $47.00 / +0.9 (+1.95%) 10/13/21 Turning Point, EQRx team to evaluate elzovantinib/aumolertinib combo in NSCLC 10/08/21 Turning Point Therapeutics presents TRIDENT-1 clinical data for repotrectinib 10/07/21 Turning Point Therapeutics provides regulatory update 10/07/21 Turning Point presents updated preliminary clinical data for elzovantinib RVMD Revolution Medicines $27.77 / +0.385 (+1.41%) 06/24/21 Revolution Medicines publishes data on mTORC1-selective inhibitors 06/10/21 Revolution Medicines to host webcast on studies of RAS inhibitors 05/03/21 Revolution Medicines highlights board of directors nominees for upcoming meeting 04/30/21 Revolution Medicines does not expect RMC-4630, sotorasib data in 2021 RHHBY Roche $48.22 / -0.01 (-0.02%) 10/13/21 Roche says new long-term data reinforce benefit of ocrelizumab in relapsing MS 10/11/21 Sarepta announces functional data from SRP-9001 development program 10/08/21 Roche's gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's 10/05/21 Genentech to present new Ocrevus, Enspryng data at ECTRIMS NVS Novartis $82.47 / +0.425 (+0.52%) 10/11/21 Novartis' Sandoz completes acquisition of GSK's cephalosporin business 10/06/21 Rafael names Mary Margaret Huizinga as chief development and medical officer 10/01/21 Sandoz resolves legacy U.S. federal government civil investigation 10/01/21 Three generic drug makers to pay $447.2M to settle price-fixing claims, DOJ says MRTX Mirati Therapeutics $171.89 / -6.27 (-3.52%) 10/07/21 Mirati, Sanofi to collaborate on adagrasib-SHP2 Inhibitor combo 09/20/21 Mirati Therapeutics announces results from Phase 2 study of MRTX-500 09/20/21 Mirati Therapeutics appoints David Meek as Chief Executive Officer 09/20/21 Mirati Therapeutics announce Phase 2 topline results for adagrasib MKKGY Merck KGaA $44.51 / +1.15 (+2.65%) 06/14/21 G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela AMGN Amgen $203.70 / +1.63 (+0.81%) 10/08/21 AstraZeneca announces Tezepelumab granted orphan drug designation 10/07/21 Amgen reports Phase 1b data from Lumakras combination in cancer 10/07/21 Amgen, Neumora enter collaboration to advance neuroscience discovery 10/04/21 BioMarin hires Bernstein as CMO, Vedantham as senior VP TPTX RHHBY NVS MKKGY MRTX AMGN RVMD TPTX Turning Point Therapeutics $47.00 / +0.9 (+1.95%) 10/12/21 H.C. Wainwright Turning Point price target lowered to $162 from $178 at H.C. Wainwright 10/11/21 JMP Securities Turning Point downgraded to Market Perform from Outperform at JMP Securities 10/08/21 Roth Capital Turning Point selloff brings 'bargain value,' says Roth Capital 10/08/21 Wedbush Turning Point Therapeutics price target lowered to $125 from $166 at Wedbush RHHBY Roche $48.22 / -0.01 (-0.02%) 10/13/21 Morgan Stanley Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley 09/20/21 Citi Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote 09/09/21 RBC Capital Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital 09/07/21 UBS Roche price target raised to CHF 350 from CHF 345 at UBS NVS Novartis $82.47 / +0.425 (+0.52%) 10/12/21 Berenberg Novartis price target lowered to CHF 88 from CHF 96 at Berenberg 10/08/21 UBS Novartis price target lowered to CHF 92 from CHF 95 at UBS 09/29/21 Stifel Blueprint Medicines rersumed with a Hold at Stifel 09/20/21 Deutsche Bank Novartis downgraded to Sell from Hold at Deutsche Bank MKKGY Merck KGaA $44.51 / +1.15 (+2.65%) 09/17/21 Morgan Stanley Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley 09/13/21 Deutsche Bank Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank 09/10/21 JPMorgan Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan 09/02/21 Barclays Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays MRTX Mirati Therapeutics $171.89 / -6.27 (-3.52%) 09/22/21 Stifel Mirati Therapeutics initiated with a Buy at Stifel 09/22/21 Citi Mirati Therapeutics price target raised to $244 from $232 at Citi 09/21/21 Oppenheimer Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer 09/07/21 JPMorgan Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan AMGN Amgen $203.70 / +1.63 (+0.81%) 10/04/21 Piper Sandler Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler 09/23/21 Daiwa Amgen downgraded to Neutral from Outperform at Daiwa RVMD Revolution Medicines $27.77 / +0.385 (+1.41%) 09/22/21 Stifel Revolution Medicines initiated with a Hold at Stifel 08/17/21 H.C. Wainwright Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright 08/12/21 Fly Intel: Top five analyst downgrades 08/12/21 Guggenheim Revolution Medicines price target lowered to $34 from $52 at Guggenheim TPTX RVMD RHHBY NVS MRTX AMGN TPTX Turning Point Therapeutics $47.00 / +0.9 (+1.95%) 08/09/21 Turning Point Therapeutics reports Q2 EPS (1.14c), consensus ($1.21) RVMD Revolution Medicines $27.77 / +0.385 (+1.41%) 08/11/21 Revolution Medicines reports Q2 EPS (60c), consensus (48c) 05/10/21 Revolution Medicines reports Q1 EPS (53c), consensus (52c) RHHBY Roche $48.22 / -0.01 (-0.02%) 07/22/21 Roche reports 1H21 core EPS CHF10.56 vs. CHF10.44 last year 04/21/21 Roche reports Q1 group sales CHF 14.93B vs. CHF 15.14B last year NVS Novartis $82.47 / +0.425 (+0.52%) 07/21/21 Novartis continues to expect FY21 core operating income to grow mid single digit 07/21/21 Novartis reports Q2 core EPS $1.66, consensus $1.52 04/27/21 Novartis sees FY21 core operating income to grow mid single digit percentage 04/27/21 Novartis reports Q1 core EPS $1.52, consensus $1.59 MRTX Mirati Therapeutics $171.89 / -6.27 (-3.52%) 08/05/21 Mirati Therapeutics reports Q2 EPS ($3.23), consensus ($2.40) 05/06/21 Mirati Therapeutics reports Q1 EPS ($2.67), consensus ($2.13) AMGN Amgen $203.70 / +1.63 (+0.81%) 08/03/21 Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.34 08/03/21 Amgen reports Q2 adjusted EPS $4.38, consensus $4.06 08/03/21 Notable companies reporting after market close 04/27/21 Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.80 04 Feb 28 Oct 27 Oct RHHBY NVS RHHBY Roche $48.22 / -0.01 (-0.02%) 09/09/21 Biden administration plans to lower prescription drug prices, WSJ reports 08/04/21 SoftBank builds $5B stake in Roche, Bloomberg reports 07/01/21 Roche won't confirm report of filing for approval of Alzheimer's drug, STAT says 06/12/21 Lilly, Roche may benefit from approval of Biogen Alzheimer's drug, Barron's says NVS Novartis $82.47 / +0.425 (+0.52%) 10/13/21 Drugmakers find new cancer risk in blood pressure drugs, Bloomberg says 07/21/21 Novartis CEO tells CNBC he still sees lower rates of non-COVID diagnoses 07/21/21 Novartis working to secure lead in market for new cancer treatment, CEO tells FT RHHBY NVS MRTX AMGN RHHBY Roche $48.22 / -0.01 (-0.02%) 09/27/21 Acceleron up amid report of talks, Cowen says $180 per share 'too low' a price 09/07/21 Wall Street in Fives - Must Read Lists for Tuesday 09/07/21 Wall Street in Fives - Must Read Lists at Midday 09/07/21 Fly Intel: Pre-market Movers NVS Novartis $82.47 / +0.425 (+0.52%) 09/20/21 Wall Street in Fives - Must Read Lists for Monday 09/20/21 Wall Street in Fives - Must Read Lists at Midday 07/21/21 Wall Street in Fives - Must Read Lists at Midday 05/18/21 Before the Move: Watch Allogene ahead of ALLO-501 update MRTX Mirati Therapeutics $171.89 / -6.27 (-3.52%) 06/24/21 Fly Intel: After-Hours Movers AMGN Amgen $203.70 / +1.63 (+0.81%) 05/28/21 Wall Street in Fives - Must Read Lists for Friday 04/27/21 Fly Intel: After-Hours Movers 10/14/21 Healthcare 10/26/21 63rd Annual ASTRO Meeting 2021 11/08/21 PPharma Marketing USA 11/09/21 30th Annual Virtual Healthcare Conference 11/16/21 2021 Virtual Healthcare Conference 11/02/21 Amgen - AMGN 12/01/21 PDUFA Date for Tecentriq 12/19/21 PDUFA Date for Otezla NVS AMGN NVS Novartis $82.47 / +0.425 (+0.52%) 10/04/21 Novartis put volume heavy and directionally bearish AMGN Amgen $203.70 / +1.63 (+0.81%) 07/21/21 Unusually active option classes on open July 21st 07/08/21 Early notable gainers among liquid option names on July 8th 06/28/21 Amgen put volume heavy and directionally bearish 06/10/21 Unusually active option classes on open June 10th
Conference/Events	Stifel healthcare analysts to hold an analyst/industry conference call » 10:30 10/11/21 10/11 10:30 10/11/21 10:30 TPTX Turning Point Therapeutics $46.08 / -1.61 (-3.38%) , RHHBY Roche $49.89 / +1.84 (+3.83%) , NVS Novartis $82.95 / +0.105 (+0.13%) , MKKGY Merck KGaA $43.18 / -0.0125 (-0.03%) , MRTX Mirati Therapeutics $167.96 / -0.275 (-0.16%) , AMGN Amgen $209.50 / +0.6 (+0.29%) , RVMD Revolution Medicines $27.66 / -0.12 (-0.43%) Healthcare Analysts,… Healthcare Analysts, along with Dr. David Ross Camidge and Dr. Vamsidhar Velcheti, discuss how TPTX's repotrectinib safety data might inform 1L or 2L market share in ROS1+ NSCLC, the opportunity for TPTX's TPX-022 MET inhibitor in METex14 NSCLC and Amgen's Lumakras KRAS G12C NSCLC launch on an Analyst/Industry conference call to be held on October 14 at 3 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TPTX RVMD RHHBY NVS MRTX MKKGY AMGN TPTX Turning Point Therapeutics $46.08 / -1.61 (-3.38%) 10/08/21 Turning Point Therapeutics presents TRIDENT-1 clinical data for repotrectinib 10/07/21 Turning Point Therapeutics provides regulatory update 10/07/21 Turning Point presents updated preliminary clinical data for elzovantinib 10/07/21 Turning Point presents updated preliminary clinical data for repotrectinib RVMD Revolution Medicines $27.66 / -0.12 (-0.43%) 06/24/21 Revolution Medicines publishes data on mTORC1-selective inhibitors 06/10/21 Revolution Medicines to host webcast on studies of RAS inhibitors 05/03/21 Revolution Medicines highlights board of directors nominees for upcoming meeting 04/30/21 Revolution Medicines does not expect RMC-4630, sotorasib data in 2021 RHHBY Roche $49.89 / +1.84 (+3.83%) 10/11/21 Sarepta announces functional data from SRP-9001 development program 10/08/21 Roche's gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's 10/05/21 Genentech to present new Ocrevus, Enspryng data at ECTRIMS 10/04/21 Sarepta announces initiation of EMBARK study of SRP-9001 NVS Novartis $82.95 / +0.105 (+0.13%) 10/11/21 Novartis' Sandoz completes acquisition of GSK's cephalosporin business 10/06/21 Rafael names Mary Margaret Huizinga as chief development and medical officer 10/01/21 Sandoz resolves legacy U.S. federal government civil investigation 10/01/21 Three generic drug makers to pay $447.2M to settle price-fixing claims, DOJ says MRTX Mirati Therapeutics $167.96 / -0.275 (-0.16%) 10/07/21 Mirati, Sanofi to collaborate on adagrasib-SHP2 Inhibitor combo 09/20/21 Mirati Therapeutics announces results from Phase 2 study of MRTX-500 09/20/21 Mirati Therapeutics appoints David Meek as Chief Executive Officer 09/20/21 Mirati Therapeutics announce Phase 2 topline results for adagrasib MKKGY Merck KGaA $43.18 / -0.0125 (-0.03%) 06/14/21 G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela AMGN Amgen $209.50 / +0.6 (+0.29%) 10/08/21 AstraZeneca announces Tezepelumab granted orphan drug designation 10/07/21 Amgen reports Phase 1b data from Lumakras combination in cancer 10/07/21 Amgen, Neumora enter collaboration to advance neuroscience discovery 10/04/21 BioMarin hires Bernstein as CMO, Vedantham as senior VP TPTX RHHBY NVS MKKGY MRTX AMGN RVMD TPTX Turning Point Therapeutics $46.08 / -1.61 (-3.38%) 10/11/21 JMP Securities Turning Point downgraded to Market Perform from Outperform at JMP Securities 10/08/21 Roth Capital Turning Point selloff brings 'bargain value,' says Roth Capital 10/08/21 Wedbush Turning Point Therapeutics price target lowered to $125 from $166 at Wedbush 10/07/21 Wells Fargo Turning Point Therapeutics price target lowered to $120 from $160 at Wells Fargo RHHBY Roche $49.89 / +1.84 (+3.83%) 09/20/21 Citi Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote 09/09/21 RBC Capital Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital 09/07/21 UBS Roche price target raised to CHF 350 from CHF 345 at UBS 08/02/21 JPMorgan Roche price target raised to CHF 360 from CHF 310 at JPMorgan NVS Novartis $82.95 / +0.105 (+0.13%) 10/08/21 UBS Novartis price target lowered to CHF 92 from CHF 95 at UBS 09/29/21 Stifel Blueprint Medicines rersumed with a Hold at Stifel 09/20/21 Deutsche Bank Novartis downgraded to Sell from Hold at Deutsche Bank MKKGY Merck KGaA $43.18 / -0.0125 (-0.03%) 09/17/21 Morgan Stanley Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley 09/13/21 Deutsche Bank Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank 09/10/21 JPMorgan Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan 09/02/21 Barclays Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays MRTX Mirati Therapeutics $167.96 / -0.275 (-0.16%) 09/22/21 Stifel Mirati Therapeutics initiated with a Buy at Stifel 09/22/21 Citi Mirati Therapeutics price target raised to $244 from $232 at Citi 09/21/21 Oppenheimer Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer 09/07/21 JPMorgan Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan AMGN Amgen $209.50 / +0.6 (+0.29%) 10/04/21 Piper Sandler Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler 09/23/21 Daiwa Amgen downgraded to Neutral from Outperform at Daiwa RVMD Revolution Medicines $27.66 / -0.12 (-0.43%) 09/22/21 Stifel Revolution Medicines initiated with a Hold at Stifel 08/17/21 H.C. Wainwright Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright 08/12/21 Fly Intel: Top five analyst downgrades 08/12/21 Guggenheim Revolution Medicines price target lowered to $34 from $52 at Guggenheim TPTX RVMD RHHBY NVS MRTX AMGN TPTX Turning Point Therapeutics $46.08 / -1.61 (-3.38%) 08/09/21 Turning Point Therapeutics reports Q2 EPS (1.14c), consensus ($1.21) RVMD Revolution Medicines $27.66 / -0.12 (-0.43%) 08/11/21 Revolution Medicines reports Q2 EPS (60c), consensus (48c) 05/10/21 Revolution Medicines reports Q1 EPS (53c), consensus (52c) RHHBY Roche $49.89 / +1.84 (+3.83%) 07/22/21 Roche reports 1H21 core EPS CHF10.56 vs. CHF10.44 last year 04/21/21 Roche reports Q1 group sales CHF 14.93B vs. CHF 15.14B last year NVS Novartis $82.95 / +0.105 (+0.13%) 07/21/21 Novartis continues to expect FY21 core operating income to grow mid single digit 07/21/21 Novartis reports Q2 core EPS $1.66, consensus $1.52 04/27/21 Novartis sees FY21 core operating income to grow mid single digit percentage 04/27/21 Novartis reports Q1 core EPS $1.52, consensus $1.59 MRTX Mirati Therapeutics $167.96 / -0.275 (-0.16%) 08/05/21 Mirati Therapeutics reports Q2 EPS ($3.23), consensus ($2.40) 05/06/21 Mirati Therapeutics reports Q1 EPS ($2.67), consensus ($2.13) AMGN Amgen $209.50 / +0.6 (+0.29%) 08/03/21 Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.34 08/03/21 Amgen reports Q2 adjusted EPS $4.38, consensus $4.06 08/03/21 Notable companies reporting after market close 04/27/21 Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.80 04 Feb 28 Oct 27 Oct RHHBY NVS RHHBY Roche $49.89 / +1.84 (+3.83%) 09/09/21 Biden administration plans to lower prescription drug prices, WSJ reports 08/04/21 SoftBank builds $5B stake in Roche, Bloomberg reports 07/01/21 Roche won't confirm report of filing for approval of Alzheimer's drug, STAT says 06/12/21 Lilly, Roche may benefit from approval of Biogen Alzheimer's drug, Barron's says NVS Novartis $82.95 / +0.105 (+0.13%) 07/21/21 Novartis CEO tells CNBC he still sees lower rates of non-COVID diagnoses 07/21/21 Novartis working to secure lead in market for new cancer treatment, CEO tells FT RHHBY NVS MRTX AMGN RHHBY Roche $49.89 / +1.84 (+3.83%) 09/27/21 Acceleron up amid report of talks, Cowen says $180 per share 'too low' a price 09/07/21 Wall Street in Fives - Must Read Lists for Tuesday 09/07/21 Wall Street in Fives - Must Read Lists at Midday 09/07/21 Fly Intel: Pre-market Movers NVS Novartis $82.95 / +0.105 (+0.13%) 09/20/21 Wall Street in Fives - Must Read Lists for Monday 09/20/21 Wall Street in Fives - Must Read Lists at Midday 07/21/21 Wall Street in Fives - Must Read Lists at Midday 05/18/21 Before the Move: Watch Allogene ahead of ALLO-501 update MRTX Mirati Therapeutics $167.96 / -0.275 (-0.16%) 06/24/21 Fly Intel: After-Hours Movers AMGN Amgen $209.50 / +0.6 (+0.29%) 05/28/21 Wall Street in Fives - Must Read Lists for Friday 04/27/21 Fly Intel: After-Hours Movers 11/08/21 PPharma Marketing USA 12/01/21 PDUFA Date for Tecentriq 12/19/21 PDUFA Date for Otezla 10/13/21 Turning Point Therapeutics NVS AMGN NVS Novartis $82.95 / +0.105 (+0.13%) 10/04/21 Novartis put volume heavy and directionally bearish AMGN Amgen $209.50 / +0.6 (+0.29%) 07/21/21 Unusually active option classes on open July 21st 07/08/21 Early notable gainers among liquid option names on July 8th 06/28/21 Amgen put volume heavy and directionally bearish 06/10/21 Unusually active option classes on open June 10th
Recommendations	Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley » 12:58 09/17/21 09/17 12:58 09/17/21 12:58 MKKGY Merck KGaA $46.38 / -0.45 (-0.96%) Morgan Stanley analyst… Morgan Stanley analyst Mark Purcell raised the firm's price target on Merck KGaA to EUR 200 from EUR 185 and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< Company News Street Research MKKGY Merck KGaA $46.38 / -0.45 (-0.96%) 06/14/21 G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela 03/18/21 Exelixis enters STELLAR-001 pact, supply agreement with Merck KGaA and Pfizer MKKGY Merck KGaA $46.38 / -0.45 (-0.96%) 09/13/21 Deutsche Bank Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank 09/10/21 JPMorgan Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan 09/02/21 Barclays Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays 08/10/21 Morgan Stanley Merck KGaA price target raised to EUR 185 from EUR 145 at Morgan Stanley
Recommendations	Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank » 15:01 09/13/21 09/13 15:01 09/13/21 15:01 MKKGY Merck KGaA $47.98 / -0.87 (-1.78%) Deutsche Bank analyst… Deutsche Bank analyst Falko Friedrichs raised the firm's price target on Merck KGaA to EUR 240 from EUR 220 and keeps a Buy rating on the shares. ShowHide Related Items >><< Company News Street Research MKKGY Merck KGaA $47.98 / -0.87 (-1.78%) 06/14/21 G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela 03/18/21 Exelixis enters STELLAR-001 pact, supply agreement with Merck KGaA and Pfizer MKKGY Merck KGaA $47.98 / -0.87 (-1.78%) 09/10/21 JPMorgan Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan 09/02/21 Barclays Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays 08/10/21 Morgan Stanley Merck KGaA price target raised to EUR 185 from EUR 145 at Morgan Stanley 08/09/21 Deutsche Bank Merck KGaA price target raised to EUR 220 from EUR 155 at Deutsche Bank

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial